|
|
Volumn 14, Issue 7, 2004, Pages 486-
|
|
Joint statement on the U.S. Food and Drug Administration's decision regarding bioequivalence of levothyroxine sodium
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
LEVOTHYROXINE;
BIOEQUIVALENCE;
DECISION MAKING;
FOOD AND DRUG ADMINISTRATION;
HEART ATRIUM FIBRILLATION;
HUMAN;
HYPERCHOLESTEROLEMIA;
HYPOTHYROIDISM;
ISCHEMIC HEART DISEASE;
OSTEOPOROSIS;
PREMATURE LABOR;
PRIORITY JOURNAL;
SHORT SURVEY;
HUMANS;
THERAPEUTIC EQUIVALENCY;
THYROID DISEASES;
THYROXINE;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 3542991444
PISSN: 10507256
EISSN: None
Source Type: Journal
DOI: 10.1089/1050725041517138 Document Type: Short Survey |
|
Times cited : (46)
|
|
References (0)
|